Biotest AG
BIESF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $726,200 | $684,600 | $516,100 | $515,600 |
| % Growth | 6.1% | 32.6% | 0.1% | – |
| Cost of Goods Sold | $502,400 | $404,300 | $391,200 | $434,900 |
| Gross Profit | $223,800 | $280,300 | $124,900 | $80,700 |
| % Margin | 30.8% | 40.9% | 24.2% | 15.7% |
| R&D Expenses | $56,800 | $74,900 | $50,500 | $54,500 |
| G&A Expenses | $38,400 | $30,600 | $31,700 | $30,100 |
| SG&A Expenses | $88,300 | $81,000 | $80,700 | $81,200 |
| Sales & Mktg Exp. | $49,900 | $50,400 | $49,000 | $51,100 |
| Other Operating Expenses | -$15,800 | -$22,500 | $0 | $0 |
| Operating Expenses | $129,300 | $136,800 | $133,400 | $132,800 |
| Operating Income | $94,500 | $143,500 | -$16,600 | -$47,100 |
| % Margin | 13% | 21% | -3.2% | -9.1% |
| Other Income/Exp. Net | -$48,000 | -$37,200 | -$14,200 | -$15,500 |
| Pre-Tax Income | $46,500 | $106,300 | -$30,800 | -$62,600 |
| Tax Expense | $20,200 | -$20,700 | $800 | $700 |
| Net Income | $26,400 | $127,000 | -$31,700 | -$63,400 |
| % Margin | 3.6% | 18.6% | -6.1% | -12.3% |
| EPS | 0.71 | 3.21 | -0.8 | -1.61 |
| % Growth | -77.9% | 501.2% | 50.3% | – |
| EPS Diluted | 0.71 | 3.21 | -0.8 | -1.6 |
| Weighted Avg Shares Out | 37,200 | 39,571 | 39,571 | 39,571 |
| Weighted Avg Shares Out Dil | 39,571 | 39,571 | 39,571 | 39,571 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,070 | $1,800 | $856 | $200 |
| Interest Expense | $32,920 | $40,000 | $23,974 | $13,200 |
| Depreciation & Amortization | $40,600 | $35,900 | $35,800 | $31,100 |
| EBITDA | $120,400 | $182,200 | $24,700 | -$18,300 |
| % Margin | 16.6% | 26.6% | 4.8% | -3.5% |